Bald man arthritis drug recent news is a medical breakthrough hitting headlines as it reportedly showcased amazing results - regrowing a bald head into a full head of hair. According to reports, a 25-year-old bald man arthritis drug may just prove a cure for alopecia universalis, an autoimmune disease that caused the man to lose all of his body hair.
According to the New York Daily News, this bald man arthritis drug study is called tofacitinib citrate, an FDA-approved rheumatoid arthritis drug.
Scientists and University doctors at Yale University said that the study of the bald man arthritis drug trial spanned a total of eight months. The unnamed man who is 25 years old at the time of the study has nearly lost all of his body hair due to alopecia universalis. After the bald man arthritis drug was taken, which is also known as tofacitinib citrate and intended for rheumatoid arthritis, the man reportedly grew back a full head of hair. Along with head hair, the Daily Mail reports that hair on other parts of his body also grew back including his eyebrows, eyelashes, hair on the face and armpit, according to the researchers.
The young man also has plaque psoriasis, a condition causing red, scaly patches on the skin, along with the autoimmune disease alopecia universalis.
According to Tech Times, alopecia universalis is a disease which has no long-term cure yet. The disease leaves everyone with the condition with barely any hair in the body. Prior to the bald man arthritis drug treatment, the young reportedly had little hair on his head where he also had psoriasis plaques. As such, he was referred for psoriasis treatment at the Yale Dermatology, which turned out to be successful with the bald man arthritis drug treatment.
According to reports, the young man's bald man arthritis drug treatment case is the first of its kind to have become successful.
Dr. Brett A. King, senior author of the study published in the 'Journal of Investigative Dermatology' and dermatology assistant professor at Yale School of Medicine said that he believed the FDA-approved bald man arthritis drug, tofacitinib citrate, to be powerful enough to deal with both of the patient's conditions.
After initially taking the bald man arthritis drug for two months with a daily dosage of 10 mg, the young man's psoriasis reportedly showed signs of improvements. His facial hair and scalp eventually grew after seven years. Because of the positive signs administering the bald man arthritis drug, the doctors boosted his daily dosage to 15 mg for three months. The patient eventually regrew his scalp hair, eyelashes, eyebrows, armpit and facial hair.
Dr. King said in a release, 'The results are exactly what we hoped for.' He also termed the bald man arthritis drug results as a 'huge step forward' for alopecia universalis treatment, which before the study, virtually had no sort of cure.
Dr. King added, 'While it's one case, we anticipated the successful treatment of this man based on our current understanding of the disease and the drug. We believe the same results will be duplicated in other patients, and we plan to try.'
King explained the process by which the bald man arthritis drug works. He said that it attacks the immune system on the hair follicles which in turn triggers hair regrowth in people with alopecia universalis.
Meanwhile, Dr. Brittany G. Craiglow, the study's co-author said that the other good side of the bald man arthritis drug is that it has no abnormalities nor side effects in the lab tests.
Bald man arthritis drug is indeed a breakthrough in the medical world, as well for people with alopecia and psoriasis. Because of the amazing success of the study, King reportedly submitted a proposal for a clinical trial which transfers the bald man arthritis drug in cream form in order to treat patients with alopecia areata.
Click here to learn more about the study [pdf], 'Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis, was published online by the Journal of Investigative Dermatology.'
This article is copyrighted by Travelers Today, the travel news leader
